ISSN 1671-5411 CN 11-5329/R
Abhishek C Sawant, Arnav Kumar, Wilmon Mccray, Sheldon Tetewsky, Linda Parone, Srilekha Sridhara, Meghana Prakash Hiriyur Prakash, Gary Tse, Tong LIU, Nidhi Kanwar, Aishwarya Bhardwaj, Sahoor Khan, Christopher Manion, Ankush Lahoti, Ashish Pershad, Peter Elkin, John Corbelli. Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: a national veterans affairs database study. J Geriatr Cardiol 2019; 16(9): 706-709. doi: 10.11909/j.issn.1671-5411.2019.09.006
Citation: Abhishek C Sawant, Arnav Kumar, Wilmon Mccray, Sheldon Tetewsky, Linda Parone, Srilekha Sridhara, Meghana Prakash Hiriyur Prakash, Gary Tse, Tong LIU, Nidhi Kanwar, Aishwarya Bhardwaj, Sahoor Khan, Christopher Manion, Ankush Lahoti, Ashish Pershad, Peter Elkin, John Corbelli. Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: a national veterans affairs database study. J Geriatr Cardiol 2019; 16(9): 706-709. doi: 10.11909/j.issn.1671-5411.2019.09.006

Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: a national veterans affairs database study

doi: 10.11909/j.issn.1671-5411.2019.09.006
Funds:

None

  • Received Date: 2019-06-17
  • Rev Recd Date: 2019-08-30
  • Publish Date: 2019-09-28
  • Background Studies evaluating safety of warfarin and direct oral anticoagulants (DOACs) for prevention of stroke in patients with atrial fibrillation (AF) are lacking. Methods & Results All patients (n = 196,521) receiving care at veteran’s affairs with active cancer and AF from 2010–2015 were included. One-year mortality was significantly higher in unadjusted analysis with warfarin (44.9%) compared to dabigatran (25%, P P P P vs. 11.1%, 12.0%, 14.0%) was similar, however risk of hemorrhagic stroke was significantly higher among patients receiving warfarin (1.2%) compared to patients receiving dabigatran (0.5%), rivaroxaban (0.7%) and apixaban (0.8%) respectively, P = 0.04. Conclusions We demonstrated the superior safety profile of DOACs compared to warfarin among patients with underlying cancer and AF. Warfarin was associated with higher mortality, similar ischemic stroke risk but higher risk of hemorrhagic stroke.
  • loading
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (779) PDF downloads(431) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return